The global clinical trial landscape of lung cancer cellular therapy current status trends and scientific challenges Authors: Chang Song, Dong-Sheng Lu, Chun-Yan Zhao, Zhan-Yu Xu, Hua-Jian Peng, Xin-Lin Li, Hai-Yu Zeng, Jun-Hong Li, Jian-Ji Guo, Nuo Yang Published: 2026 ABSTRACT ObjectiveThis study aims to review the development trends of clinical trials for lung cancer cellular therapy systematically, analyze the spatiotemporal distribution, research entities, cell types, target selection quantitatively, thus, trial design characteristics and reveal the evolutionary patterns, driving factors, and scientific challenges in this field. The findings are intended to provide a reference for subsequent research, policy formulation, and clinical translation.MethodsClinical trials of cellular therapies for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) worldwide up to July 2025 were retrieved. A cross-referencing strategy was applied to include interventional clinical studies in the process of excluding non-cellular therapies and records with missing key information. Two researchers independently screened and extracted data, 452 trials were included ultimately. Descriptive statistical methods were used to make analysis of core indicators, such as annual trends, geographical distribution, funding entities, target mechanisms, research phases, and trial status. Results Global clinical trials for lung cancer cellular therapy entered a rapid development phase, which started in 2016, peaked in 2024 (51 trials). Trials were highly concentrated on early stages, with Phase I and Phase I/II studies accounting for 79.9% (361/452). Only 7 Phase III studies were conducted, this gave a highlight of significant translational bottlenecks. Geographically, a bipolar driving pattern emerged between China and the United States. China experienced explosive growth post-2016 and leaded globally in trial numbers by 2024 (31 trials). Funding entities shifted from early public sector dominance to industry-led by small and medium-sized biotech companies. In terms of targets, PD-1 (25 trials) and IL-2Rα (22 trials) were the most popular, while emerging targets, for instance, cancer-testis antigen 1B and mesothelin gradually gained prominence. Mechanistically, immuno-oncology therapies and T-cell stimulators predominated. Among therapies such as CAR-T, NK, TCR-T, TIL, and DC vaccines, CAR-T and TIL, all showed the highest recent activity, while DC vaccines were relatively mature.ConclusionThis study systematically analyzed the current status and trends of global clinical trials for lung cancer cellular therapy, which demonstrated the rapid development driven by technological breakthroughs, policy support, and capital investment. Nevertheless, lung cancer cellular therapy still faces scientific challenges, such as target selection, efficacy enhancement, and safety optimization. Future research should explore deeply to give a promotion of clinical translation and application.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-026-05098-7. Introduction Lung cancer is one of the most prevalent and deadly malignancies worldwide, posing a significant public health challenge [1]. Lung cancer consistently ranks highest in mortality, as shown in the latest global cancer statistics. It places a heavy disease burden and exerts profound impacts on socioeconomic and human health [2]. From a histopathological perspective, lung cancer is primarily classified into either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), with NSCLC accounting for approximately 85% of all cases [3]. Despite revolutionary advancements have been made in lung cancer treatment over the past few decades, leading to the establishment of a comprehensive treatment system centered on surgical resection, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors (ICIs), the overall prognosis remains grim, particularly for advanced-stage patients [4, 5]. Despite the significant survival benefits offered by PD-1/PD-L1 inhibitors, the current clinical practice for lung cancer in faced with several critical challenges: First, the majority of patients are diagnosed at advanced stages, which means they may miss the optimal window for curative surgery. Secondly, the effectiveness of targeted therapies is dependent on the presence of specific driver gene mutations (e.g., EGFR, ALK, KRAS). However, these therapies are almost guaranteed to result in acquired resistance [6–9]. Third, although ICIs offer hope for long-term survival in patients without driver gene mutations, a significant proportion of patients exhibit primary or secondary resistance [10]. Therefore, there is an urgent need to develop novel therapeutic strategies. These strategies are capable to overcome existing limitations, consequently provide effective treatment options for a broader population of lung cancer patients, particularly those with refractory disease unresponsive to current therapies. In recent years, cellular immunotherapy, represented by chimeric antigen receptor T-cell (CAR-T) therapy, has achieved revolutionary breakthroughs in the field of hematologic malignancies. Multiple products have obtained regulatory approval for marketing, delivering significant survival benefits to patients with relapsed or refractory hematologic tumors [11–13]. This success not only validates the therapeutic potential of cellular therapies but has also greatly stimulated the enthusiasm of both academia and industry to extend their application to the field of solid tumors. It offers a novel paradigm for precision immunotherapy in lung cancer. By leveraging patients’ own immune cells or genetically engineered cells to directly target and kill tumor cells, cellular therapy provides new possibilities for lung cancer treatment [14]. The field of lung cancer research has seen a surge of interest in cellular therapies such as CAR-T therapy, T-cell receptor-engineered T-cell (TCR-T) therapy, and natural killer (NK) cellular therapy. This is due to the growing understanding of the tumor microenvironment and immune evasion mechanisms in lung cancer [15–20]. However, despite this vigorous development, the translational path from laboratory discoveries to widespread clinical application remains long and arduous. In recent years, with the continuous expansion of cancer immunotherapy in the field of solid tumors, numerous reviews have systematically summarized lung cancer cellular therapies from various perspectives. Several studies have focused on the preclinical and clinical research progress of CAR-T therapy in lung cancer [21–23]. Lotze et al. systematically summarized the application strategies of tumor-infiltrating lymphocytes (TILs) in the treatment of lung cancer [24]. Other studies have investigated the mechanisms of resistance and combination therapeutic strategies for cellular therapies from the perspective of the tumor microenvironment [25]. Although these studies have offered valuable insights for the field, to date, there remains a lack of research that provides a comprehensive and systematic review of this rapidly evolving domain. Specifically, a holistic overview delineating the trajectory from “bench to bedside,” coupled with an in-depth analysis of the critical scientific challenges encountered, is still needed. Therefore, this study aims to systematically review and analyze the progress and dynamics of lung cancer cellular therapy in global clinical trials. Drawing on authoritative clinical trial databases, we will provide a quantitative analysis of the developmental trajectory and current landscape of this field from multiple dimensions. Spatiotemporal distribution, research entities, cell types, mechanisms of action, target selection, and trial design are all covered. Materials and methods Data sources and search strategy The data for this study were identified using the INFORMA pharmaceutical database as a primary retrieval tool to construct a comprehensive index of relevant trials. Given that INFORMA systematically aggregates information from over 30,000 global sources—including public repositories like ClinicalTrials.gov, the European Union Clinical Trials Register (EU-CTR), and the WHO International Clinical Trials Registry Platform (ICTRP)—it provides a broader scope for trial discovery than any single public database. Preliminary analysis indicated that utilizing INFORMA as an indexing tool allowed us to identify approximately 31% more relevant clinical trial records compared to searching ClinicalTrials.gov alone (10,786 vs. 7,419), capturing numerous small-scale exploratory trials and those conducted in the Asia-Pacific region that are often underrepresented in US-centric registries [26]. Crucially, while INFORMA was used to generate the initial list of trial entries, the detailed screening, extraction, and analysis of trial data were performed by accessing the original records in publicly available repositories. Specifically, two researchers independently screened the titles and abstracts derived from the INFORMA index. For trials passing the initial screening, full details were extracted directly from their respective primary public registries (e.g., ClinicalTrials.gov, EU-CTR) or through supplementary public sources such as conference abstracts and official company publications. This approach ensured that our final dataset and subsequent analyses were based on information that is publicly accessible and verifiable. Trials for which core information could not be verified through these public channels were excluded. In order to capture the latest advancements in lung cancer cellular therapy comprehensively and accurately, the research team conducted a systematic search of the database in July 2025. The search strategy employed a cross-referencing approach based on disease area and intervention type. The core search query was constructed as follows: [(Disease is Oncology: Lung, Non-Small Cell) OR (Disease is Oncology: Lung, Small Cell)] AND (Drug Type is Biological > Cellular). The aim of this query was to cover all clinical trial projects involving the two major subtypes of lung cancer: NSCLC and SCLC precisely. The final search results encompassed various adoptive cellular immunotherapies, including CAR-T therapy, TCR-T therapy, tumor-infiltrating lymphocyte (TIL) therapy, NK cellular therapy, and dendritic cell (DC) vaccines. All these were done to maximize the sensitivity and specificity of the search, no time range restrictions were applied, and non-clinical records related to animal experiments or in vitro studies were manually excluded. In order to capture the latest advancements in lung cancer cellular therapy comprehensively and accurately, the research team conducted a systematic search of the database in July 2025. The search strategy employed a cross-referencing approach based on disease area and intervention type. The core search query was constructed as follows: [(Disease is Oncology: Lung, Non-Small Cell) OR (Disease is Oncology: Lung, Small Cell)] AND (Drug Type is Biological > Cellular). The aim of this query was to cover all clinical trial projects involving the two major subtypes of lung cancer: NSCLC and SCLC precisely. The final search results encompassed various adoptive cellular immunotherapies, including CAR-T therapy, TCR-T therapy, tumor-infiltrating lymphocyte (TIL) therapy, NK cellular therapy, and dendritic cell (DC) vaccines. All these were done to maximize the sensitivity and specificity of the search, no time range restrictions were applied, and non-clinical records related to animal experiments or in vitro studies were manually excluded. Data screening and extraction process To ensure objectivity and rigor in the screening process, clear inclusion and exclusion criteria were established. Inclusion criteria required that trials met all of the following conditions: (1) the study explicitly focused on cellular therapy for lung cancer; (2) the type of cellular product, mechanism of action, or therapeutic target was detailed; (3) the trial design was interventional; and (4) the intervention involved any form of adoptive cellular immunotherapy. Exclusion criteria covered: (1) missing key information, such as cell type or mechanism of action; (2) severely incomplete datasets; (3) non-interventional studies, such as observational studies, epidemiological surveys, or registry studies; (4) non-cellular therapies, such as cytokines, antibody drugs, chemotherapy, or radiotherapy; and (5) duplicate clinical trial records. The data was screened and extracted independently by two researchers based on these criteria. The screening process employed a hierarchical strategy. Initial screening was based on titles and abstracts. This was to exclude obviously ineligible records. Full-text assessment of the remaining records to determine final inclusion. In cases of disagreement, a consensus was reached through discussion and consultation with a third senior researcher. For trials with missing or ambiguous target information, cross-validation and supplementation were conducted. This was done by reviewing related publications, conference abstracts, and official information from pharmaceutical companies. Trials for which core information could not be confirmed after multiple verifications, such trials were excluded from the final analysis. A total of 452 clinical trials were ultimately identified for analysis through this systematic screening process. Data from all included studies were collected according to predefined extraction specifications and entered into a standardized form. The extracted data covered a wide range of dimensions in order to provide a comprehensive picture of the landscape of development landscape, including trial registration information (e.g., trial title), spatiotemporal distribution characteristics (registration year, sponsor country, geographic location of research centers), research entity characteristics (sponsor type, collaboration models), intervention characteristics (specific cellular therapy type, mechanism of action, molecular target), and trial design characteristics (study phase, current status, enrolled participant size). Statistical analysis Frequencies and proportions were used to analyse categorical variables (e.g., trial phase, cellular therapy type, funding entity) using descriptive statistical methods with distribution characteristics visualized through charts. For continuous variables (e.g., registration year), means, medians were employed according to data distribution. To reveal the historical evolution of this field, a bar chart depicting the annual number of trials was generated. Results Overall trends in lung cancer cellular therapy clinical trials As shown in Fig. 1, the number of clinical trials in this field remained in the single-digit range from 1995 to 2015, reflecting the early stage of technological exploration and concept validation. From 2016 onwards, however, the number of trials began to grow steadily and robustly. This turning point coincided with the breakthrough efficacy and regulatory approval of CAR-T therapy in hematologic malignancies. This highlighted the significant “spillover effect” of major technological advancements on solid tumor treatment. Between 2020 and 2024, the field underwent a period of swift development, peaking in 2024 with 51 trials. This explosive growth may be attributed to global policy support. It may also be attributed to capital investment in cellular therapy research. Another factor is the widespread attention to nucleic acid platform technologies. This is driven by the success of mRNA vaccines during the COVID-19 pandemic. There should be awareness of the fact the data for 2025 were only available up to July and there is no inclusion of complete annual records. Fig. 1Annual change statistics of the number of experiments in the global research field from 1995 to 2025 Annual change statistics of the number of experiments in the global research field from 1995 to 2025 Completion status and phases of lung cancer cellular therapy clinical trials With regard to the current status of trials, 126 studies were categorized as “Completed” and an equal number (126) as “Open”, indicating a balanced and active research landscape that reflects effective allocation of resources and steady advancement of research initiatives (Fig. 2A). However, with 101 trials classified as “Terminated” trials, the number was notably high, with “Closed” and “Temporarily Closed” trials numbering 24 and 1, respectively. This further suggests dynamic changes and potential uncertainties in the research environment. Furthermore, 74 trials were “Planned,” showcasing ongoing innovation in the field. When it came to trial phases, Phase I trials (247) and Phase I/II trials (114) significantly outnumbered other phases, indicating a focus on early exploratory work. In contrast, Phase II and Phase III trials numbered 77 and 7, respectively. This shows a marked decline. It also reflects bottlenecks in translating early research into clinical applications (Fig. 2B). Fig. 2Distribution of clinical trials by status and phase. (A Trial phase of different trial types; B Trial status of different trial types) Distribution of clinical trials by status and phase. (A Trial phase of different trial types; B Trial status of different trial types) Geographic distribution of lung cancer cellular therapy clinical trials This study analyzed the regional distribution dynamics of clinical trials from 1995 to 2025. Distinct phases of evolution and geographic shifts in global trial activity were revealed by the data(Fig. 3A–B). In the early stage (1995–2010), clinical trials were concentrated primarily, with North America (primarily the United States) leading the way in terms of annual trial numbers. During the same period, activity in Europe was relatively low, while there was minimal activity in Asia except in a few years. A pivotal shift occurred between 2015 and 2016. From this point onward, Asia, particularly China, experienced explosive growth. In 2016, China recorded 13 trials, which marked the first time the number reached double digits. This rapid growth continued, at 31 trials in 2024. The “Americas” category includes clinical trial data from North America, Central America, and South America. Stable output was maintained in North America (dominated by the United States), with annual trial numbers remaining at a high plateau (e.g., 20 trials in 2023), but its global share was seen to decline due to Asia’s rapid growth. Throughout the observation period, Europe exhibited limited growth, with consistently low annual trial numbers. In terms of collaboration models, single-country participation was dominant, accounting for 350 trials. This far exceeded dual-country (25 trials) and multi-country (27 trials) collaborations. This reflects the centralised nature of research activity and the lack of international cooperation mechanisms (Fig. 3C). Detailed data for specific regions and countries can be found in Supplementary Table 1 ~ 2. Fig. 3Regional distribution analysis of clinical trials for lung cancer cellular therapy. (A Top 5 continents; B Top 5 countries; C Analysis of collaborative patterns) Regional distribution analysis of clinical trials for lung cancer cellular therapy. (A Top 5 continents; B Top 5 countries; C Analysis of collaborative patterns) Funding sources for lung cancer cellular therapy clinical trials The temporal data in this study revealed a clear evolution in funding sources. There was a transition from public sector dominance to industry-driven initiatives, with the ecosystem becoming more heterogeneous ecosystem (Fig. 4A–B). In the early stages (around 1995–2010), research activity was centred around the National Institutes of Health/National Cancer Institute (NIH/NCI) and academic institutions, in line with traditional paradigm of government- and academia-driven translational research paradigm. However, a critical turning point occurred between 2015 and 2016. Emerging biotechnology companies like Adaptimmune began to rise. At the same time, trials sponsored by other pharmaceutical companies and academic institutions surged (e.g., trials by other pharmaceutical companies increased from 6 in 2015 to 22 in 2018). Notably, despite becoming the dominant force, the contribution of top-tier large pharmaceutical companies (Top 20 Pharma) remains relatively limited. These highlights shift in innovation sources from traditional giants to more dynamic small and medium-sized biotech companies, as well as their collaborative networks with academia. Fig. 4Evolution of clinical trial sponsors. (A Types of funding organizations; B Distribution of the top 5 sponsors for clinical trials) Evolution of clinical trial sponsors. (A Types of funding organizations; B Distribution of the top 5 sponsors for clinical trials) Targets, mechanisms, and drugs in lung cancer cellular therapy clinical trials The most advanced research foci at the target level were programmed cell death protein 1 (PD-1, 25 trials) and interleukin-2 receptor subunit alpha (IL-2Rα, 22 trials) constituted the most advanced research foci (Fig. 5A). Of particular note is the emergence of new targets, such as cancer/testis antigen 1B (16 trials) and mesothelin (16 trials), marking the transition of tumor-specific antigen-based personalized therapies from concept to clinical-scale exploration. Traditional targets such as epidermal growth factor receptor EGFR (7 trials) and erb-b2 receptor tyrosine kinase 2 (HER2, 6 trials) were also investigated. When it came to mechanisms, immuno-oncology therapy (375 trials) and T cell stimulants (235 trials) were the most popular research topics (Fig. 5B). Meanwhile, emerging mechanisms such as natural killer cell stimulants (32 trials) and live microbiome modulators (11 trials) attracted attention, broadening the range of immune regulation. In contrast, traditional mechanisms like DNA inhibitors (23 trials) and taxane microtubule inhibitors (10 trials) retained some research activity but saw a significant decline in relative proportion. Fig. 5Mechanistic analysis of clinical trials for esophageal cancer cellular therapy. (A Distribution of targets; B Distribution of mechanisms; C Distribution of tested drugs) Mechanistic analysis of clinical trials for esophageal cancer cellular therapy. (A Distribution of targets; B Distribution of mechanisms; C Distribution of tested drugs) Tumor biomarkers in lung cancer cellular therapy clinical trials Figure 6 illustrates the distribution of the top 20 tumor biomarkers in clinical trials. Epidermal growth factor receptor (EGFR) ranked first. It had 93 trials. GPT ranked second. It had (86 trials) and anaplastic lymphoma kinase (ALK) (74 trials). It is worth noting that there is a notable presence of immunotherapy-related biomarkers such as CD8A (59 trials) and PDCD1 (25 trials), which are closely associated with the successful development and clinical application of immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors). Additionally, traditional biomarkers like albumin (53 trials) and CRP (11 trials) were also observed. However, researchers conducted relatively few trials of emerging biomarkers such as MSLN (15 trials) and GPC3 (9 trials). Fig. 6The most common top 20 oncology biomarkers The most common top 20 oncology biomarkers Classification of lung cancer cellular therapy clinical trials Since the initiation of its first trial in 2016, CAR-T therapy has maintained active clinical development, with Phase I studies dominating (23 trials) and an increased number of trials being initiated in recent years (2022–2025). In terms of trial status, the majority of trials are either ongoing (16 trials) or in the planning stage (7 trials), reflecting the continued rapid development of this approach. NK cellular therapy has shown a similar growth trajectory, particularly with a significant increase in Phase I trials (14 trials) between 2021 and 2024 in particular. The majority of the trials are still ongoing (10 trials), but the relatively high termination rate (5 trials) suggests potential challenges in clinical advancement. The first trial of TCR-T therapy was conducted in 2006, and since then, the number of trials has remained relatively small, with only 11 in total. Notably, most of these trials were Phase I studies, accounting for eight out of the 11. A higher proportion of these trials are “Planned” (5 trials). TIL therapy experienced rapid development between 2022 and 2024. 14 Phase I trials were conducted. Its trial status is heavily concentrated in “Open” (13 trials). This indicates as a current clinical focus. In contrast, DC vaccines, as an earlier explored immune cell type that has been explored for longer, have a longer trial timeline (2009–2024), with slightly more Phase II studies (7 trials) and a higher proportion of “Completed” trials (9 trials), reflecting the relative maturity of this technology. However, its activity has declined in recent years. The number of HSC and CIK-related trials is limited, with CIK therapy spanning Phase I–II and including one completed randomized controlled study. This suggests the suggesting its potential value in specific clinical designs (Fig. 7). Fig. 7Distribution of trial phases and status for three lung cancer cellular therapies (A CAR-T trial status; B CAR-T trial phases; C NK cell trial status; D NK cell trial phases; E TCR trial phases; F TCR trial phases; G TIL trial status; H TIL trial phases; I DC trial status; J DC trial phases) Distribution of trial phases and status for three lung cancer cellular therapies (A CAR-T trial status; B CAR-T trial phases; C NK cell trial status; D NK cell trial phases; E TCR trial phases; F TCR trial phases; G TIL trial status; H TIL trial phases; I DC trial status; J DC trial phases) Table 1Relevant information of CIK and HSC trailsTrial IDTrial titleTrial phaseTrial statusSponsorStart dateCIK495,063A Clinical Study of CIK (Autologous Cell Immunotherapy) in Patients with Lung CancerIPlannedIndustry, all other pharmaUnknowned322,736Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung CancerIITerminatedAcademicIndustry, all other pharma2018/3/27271,229Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined with Chemotherapy for Non-Small Cell Lung CancerI/IICompletedIndustry, all other pharmaAcademic2016/2/1HSC477,487A Clinical Study of N-LIfT (HSC) in Patients with Non Small Cell Lung CancerIPlannedIndustry, all other pharmaUnknowned Table 1Relevant information of CIK and HSC trailsTrial IDTrial titleTrial phaseTrial statusSponsorStart dateCIK495,063A Clinical Study of CIK (Autologous Cell Immunotherapy) in Patients with Lung CancerIPlannedIndustry, all other pharmaUnknowned322,736Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung CancerIITerminatedAcademicIndustry, all other pharma2018/3/27271,229Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined with Chemotherapy for Non-Small Cell Lung CancerI/IICompletedIndustry, all other pharmaAcademic2016/2/1HSC477,487A Clinical Study of N-LIfT (HSC) in Patients with Non Small Cell Lung CancerIPlannedIndustry, all other pharmaUnknowned Relevant information of CIK and HSC trails Academic Industry, all other pharma Industry, all other pharma Academic Discussion This study provides a systematic analysis and comprehensive overview of the global landscape of clinical trials for lung cancer cellular therapies. It reveals the evolutionary trajectory of the field from its early stages of exploration to its current period of rapid development, and identifies the underlying driving factors. The research does more than just provide numbers for how clinical trials are spread out over space and time, as well as how target selection, mechanisms of action, and drug development trends are distributed. It also looks at how policy support, technological breakthroughs, and clinical needs on research activities. It provides a critical foundation for understanding the scientific logic, clinical translation bottlenecks, and future directions of this field (Table 1). The development of lung cancer cellular therapy exhibits distinct phased characteristics. Before 2016, the field was primarily in a phase of technological accumulation. After that, it entered a period of rapid expansion. This period of expansion, peaking in research activity between 2020 and 2024. This trajectory has been closely linked to the groundbreaking advancements in cellular therapy for hematologic malignancies, particularly the successful application of CAR-T therapy in hematologic cancers [27–29]. The approval of Novartis’s Kymriah and Gilead’s Yescarta in 2017 demonstrated unprecedented clinical efficacy of CAR-T therapy in refractory hematologic malignancies, a technological milestone that dispelled skepticism within the global academic and industrial communities regarding the feasibility of cellular therapy. The release of policy dividends significantly invigorated R&D vitality in emerging markets; combined with the global dissemination of engineering modification technologies resulting from the overcoming of early patent barriers and the massive influx of industrial capital, these factors collectively drove the rapid proliferation of exploratory trials and the emergence of a new landscape of industrialized competition. The clinical success of CAR-T therapy not only demonstrated the immense potential of cellular therapy in treating cancer but also highlighted the huge potential of this approach and has driven its exploration in solid tumors. But even though there has been a big increase in research, most clinical trials are still in the early stages (Phase I). From a global research perspective, the field of cellular therapy has undergone profound structural transformations, which have had a significant impact on the way the field is currently understood and approached. The United States’ early dominance in a single-centre model has gradually evolved into a new bipolar-driven landscape, with both the United States and China at the helm. Notably, China has experienced explosive growth in this field since 2016. This phenomenon reflects China’s strategic layout in biotechnology, policy guidance, and the unique advantages of its rapidly developing clinical research system. The demand for new treatments among China’s large patient population has also driven this progress. In 2024, lung cancer accounted for the largest proportion of newly diagnosed cancer cases, at 681,124, highlighting the urgent need for effective prevention and treatment strategies [30]. In 2015, the National Health and Family Planning Commission and the China Food and Drug Administration jointly issued the Administrative Measures for Clinical Research of Stem Cells (Trial) and the Guidelines for Quality Control and Preclinical Research of Stem Cell Preparations (Trial), laying a policy foundation for the standardized development of cellular therapy. Subsequently, the State Council printed the “Healthy China 2030” Planning Outline and the 13th Five-Year Plan for National Strategic Emerging Industries in 2016, explicitly identifying stem cells and regenerative medicine as priority development areas. In 2017, six ministries and commissions jointly released the Special Plan for Scientific and Technological Innovation in the Health Industry during the 13th Five-Year Plan Period, which for the first time included immune cellular therapy products such as CAR-T as key directions for support, followed by the inclusion of stem cells and regenerative medicine in the key industries catalog for intellectual property support by the China National Intellectual Property Administration in 2018, alongside the State Council’s approval for medical institutions in pilot free trade zones to conduct frontier clinical research on stem cells. Concurrently, China’s drug review and approval system underwent continuous deepening reform; the Marketing Authorization Holder (MAH) system, piloted in 2015 and fully implemented in 2019, permitted research institutions to act as marketing authorization holders, thereby significantly stimulating the innovation vitality of small and medium-sized biotechnology companies. On the capital front, financing in China’s biopharmaceutical sector witnessed explosive growth between 2015 and 2021, with the total amount surging from less than 10 billion RMB to a peak of 135.869 billion RMB. The influx of substantial venture capital into the cellular therapy track, coupled with the global dissemination of engineering modification technologies due to the gradual overcoming of early patent barriers, collectively drove an exponential increase in the number of exploratory trials in China starting from 2016.The “Technical Guidelines for the Development and Evaluation of Biosimilars” issued by China in 2015 and subsequent classifications of cellular therapy products have provided a clear development pathway for the industry. Implementing Marketing Authorization Holder (MAH) system in 2016, which allows research institutions to hold drug marketing authorizations, has significantly stimulated innovation among small and medium-sized biotech companies. Additionally, the “Major New Drug Innovation” national science and technology project has consistently supported cutting-edge technologies such as cellular immunotherapy, providing valuable funding at a national level. Together, these policy measures collectively form the institutional support system that has enabled China’s cellular therapy industry. As a traditional powerhouse in biomedicine, the United States has advanced innovative cancer treatments, including cellular therapy by modernising its review and accelerated pathway policies. The “Cancer Moonshot” initiative has accelerated the development of breakthrough cancer therapies, including cellular therapy, by increasing funding and promoting data sharing [31, 32]. The Oncology Center of Excellence (OCE), which was established by the FDA and authorised under the 21st Century Cures Act, has expedited the development and review of certain cancer drugs, biologics, and devices. In its first year, the OCE conducted clinical reviews of multiple products, including the first approved CAR-T therapies to be approved for advanced haematological malignancies [33]. The efficiency of anticancer drug reviews has not only been enhanced by initiatives such as the Real-Time Oncology Review (RTOR) and Project Orbis, but international simultaneous approvals have also been facilitated international simultaneous approvals, enabling promising therapies to benefit global patients more rapidly [34–36]. These review systems encouraged high-risk, high-reward investments in cellular therapy by reducing regulatory uncertainties for innovative drug companies. International multicentre research still only makes up a small part of global scientific output, as shown by the data, which reveals deep-seated “data silo” issues. These silos are not naturally occurring. They stem from the nature of data, security concerns, intellectual property, confidentiality, potential misuse or misinterpretation data. They also stem from inability to ensure subject privacy through anonymization [37]. This fragmented state, on the one hand, leads to significant waste of research resources. It also hinders the standardization of research protocols across regions and populations. This makes it difficult to gain mutual recognition from global regulatory agencies. This is because conclusions based on single-region data are difficult to recognise. This greatly limits their extrapolation and application value. In terms of research entities, the funding model, which was dominated by the National Institutes of Health/National Cancer Institute and academic institutions, has gradually been replaced by a diversified investment system centered on the industry, particularly small and medium-sized biotech companies. This shift marks the field’s transition from basic exploration to product development. It is notable that traditional large pharmaceutical companies remain relatively uninvolved, while emerging biotech companies exhibit stronger innovation vitality. While this model stimulates innovation potential, it may also lead to excessive resource concentration on short-term visible outcomes, with insufficient attention to long-term foundational exploration. At the target level, the most popular research foci are programmed cell death protein 1 (PD-1) and interleukin-2 receptor subunit alpha (IL-2Rα) constitute the most popular research foci. PD-1, as a key target of immune checkpoint inhibitors and has been extensively validated in lung cancer treatment for its critical role in regulating T cell function [38]. IL-2Rα enhances anti-tumor immune responses by activating T cells and NK cells [39–41]. Notably, emerging targets such as cancer/testis antigen 1B and mesothelin (MSLN) have also risen. Cancer-testis antigens (CTAs) are expressed during embryonic development and reactivated during tumorigenesis. The name CTA comes from how it appears in the body. After it develops in the egg, it is only found in the testes. It is not found in other normal adult tissues. To date, over 700 CTAs have been identified as being overexpressed abnormally in various cancers, with more than 90 CTAs being detected in lung cancer cells or tissues [42]. CTAs are immunogenic and can induce T cell-mediated humoral immune responses, making them highly specific targets for immunotherapy and cancer vaccines [43]. Mesothelin (MSLN) is a cell surface glycoprotein. It is primarily expressed in mesothelial tissues such as the pleura, pericardium, and peritoneum. However, it is not expressed in the parenchyma of vital organs. MSLN exhibits abnormal overexpression in various malignancies, demonstrating significant tumor specificity [44]. As a tumor-associated antigen, it plays a critical role in cancer cell survival, proliferation, migration, invasion, and drug resistance, making it an ideal target for various anti-tumor therapies, including antibodies, ADCs, immunotoxins, cancer vaccines, and CAR-T cellular therapies [45]. From a mechanism perspective, immuno-oncology therapy and T cell stimulants dominate, reflecting the groundbreaking advancements and widespread clinical application of tumor immunotherapy in recent years. The successful application of immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) in lung cancer treatment has significantly improved survival outcomes for some patients [46–48]. The exploration of emerging mechanisms such as natural killer cell stimulants and live microbiome modulators, suggests that regulating the tumor microenvironment regulation and gut microbiota in immunotherapy. Gut microbial metabolites regulate lung physiology and immune status through the gut-lung axis, including short-chain fatty acids, tryptophan derivatives, polyamines, and secondary bile acids. These metabolites influence the lung cancer immune microenvironment through the circulatory system, with carcinogenic metabolites promoting lung cancer development and anti-cancer metabolites enhancing immune responses and improving immunotherapy efficacy [49]. Research has shown that ginseng polysaccharides alter the gut microbiota and the kynurenine/tryptophan ratio, enhancing the anti-tumor effects of anti-PD-1/PD-L1 immunotherapy [50]. New possibilities for cancer treatment are offered by the rapid development of lung cancer cellular therapy, but numerous challenges are still faced in its clinical translation. First, the complexity and heterogeneity of the tumor microenvironment limit the efficacy of cellular therapy. Consequently, exploring new targets, refining cell design and formulating combination therapy strategies will be critical future research directions. Second, the complex research and production processes involved in personalised cellular therapy pose significant technical and economic barriers to clinical translation. Thus, developing efficient, low-cost production processes will be essential for its widespread application. Finally, the high concentration of clinical trials in early phases reflects significant translational bottlenecks from concept validation to confirmatory clinical studies. Therefore, an essential approach to verifying efficacy and safety will be to strengthen multicentre, large-sample clinical research. In addition to the aforementioned challenges, safety concerns constitute a pivotal factor constraining the widespread clinical application of lung cancer cellular therapies. Unlike the broad-spectrum cytotoxicity associated with traditional chemotherapy, adverse events (AEs) related to cellular therapy exhibit distinct immune-mediated characteristics, the most prominent and severe of which are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is triggered by the massive release of inflammatory cytokines (e.g., IL-6, IFN-γ) from activated immune cells, presenting with clinical manifestations ranging from fever and fatigue to life-threatening hypotension, capillary leak syndrome, and multi-organ failure. Conversely, ICANS manifests as headache, delirium, seizures, and even cerebral edema, with mechanisms potentially involving blood-brain barrier disruption and cytokine infiltration into the central nervous system [51]. Furthermore, cellular therapies for solid tumors face the unique challenge of “on-target, off-tumor” toxicity; whenever target antigens are expressed at low levels in normal tissues—such as mesothelin in pleural cells or HER2 in pulmonary epithelial cells—engineered immune cells may inadvertently attack non-tumor tissues, resulting in severe or even fatal organ damage [52]. The toxicity profile of cellular therapies is distinct compared to other treatment modalities. Relative to ICIs, cellular therapies are generally associated with a higher incidence and severity of CRS and ICANS, whereas ICIs more frequently induce persistent immune-related adverse events (e.g., pneumonitis, colitis) [53, 54]. Compared to targeted therapies (e.g., EGFR-TKIs), which primarily cause organ-specific toxicities such as rash and diarrhea, cellular therapy is predominantly characterized by acute systemic inflammatory reactions [55]. Future research should prioritize the systematic collection and reporting of AE data within clinical trial designs, establish standardized protocols for toxicity grading and management, and explore biomarkers for the early prediction of severe toxicity. These efforts are essential to more comprehensively evaluate the benefit-risk ratio of lung cancer cellular therapies and to facilitate their safe and effective clinical translation. Although this study provides a comprehensive overview of landscape and evolutionary trends of global lung cancer cellular therapy clinical trials, it has certain limitations. First, our analysis relies on the initial indexing scope provided by the INFORMA commercial database. While the platform is authoritative, but it may omit studies not registered there or included in regional databases, potentially leading to biased assessments of activity in specific regions or technical pathways. Second, the “termination” or “failure” of clinical trials in the database often lacks detailed explanations. This makes it difficult to precisely analyze the specific scientific or operational challenges behind translational bottlenecks. Finally, as the data cutoff is July 2025, the absence of complete annual trial records may impact trend analysis, which is a concern given the importance of such records in facilitating effective decision-making. In future, we will integrate multiple databases (e.g., ClinicalTrials.gov and regional databases) to address the limitations of a single data source. Through literature reviews, expert interviews, and modeling analysis, delve deeper into the specific reasons for clinical trial termination or failure. Moreover, lengthening the observation period and introducing time series analysis will enable dynamic monitoring of research trends. Future research could focus on comparative analyses of research and development strategies across specific countries or regions, the impact of transnational cooperation models on innovation outcomes, and the driving factors underlying critical turning points in time series analyses, thereby providing more targeted evidence-based foundations for promoting the balanced development and optimal strategic layout of global cellular therapies for lung cancer. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.